Plinabulin has now collected its second FDA designation, and this one targets a harder problem. The FDA granted Fast Track status to plinabulin plus docetaxel for advanced or metastatic non-squamous NSCLC without actionable genomic alterations, specifically in patients whose disease progressed after both anti-PD-(L)1 therapy and platinum-based chemotherapy. That population has few reliable options once two lines of therapy have failed, and docetaxel alone performs modestly in that setting. The designation keeps BeyondSpring’s DUBLIN-4 trial on a path toward an interim analysis with more frequent FDA communication available.
The Phase 2 signal that shaped DUBLIN-4 came from a 47-patient investigator-initiated study presented at ASCO 2026. With a median follow-up of 28.8 months after a February 2026 data cutoff, the triplet of pembrolizumab, plinabulin, and docetaxel showed durable responses in patients who had already progressed on first-line checkpoint inhibitor therapy. Those results form the mechanistic argument for DUBLIN-4, which randomizes approximately 442 patients 1:1 to plinabulin plus docetaxel or docetaxel alone.
BeyondSpring also disclosed a strategic transaction intended to fund the trial toward that planned interim analysis. The release does not detail the transaction structure or capital amount, so the financial runway it provides is unclear. What the company did confirm is that reaching the interim analysis is the near-term operational target, and the Fast Track designation gives the program a formal FDA conversation channel as enrollment builds globally. Plinabulin previously earned Breakthrough Therapy Designation from the FDA in 2020 for chemotherapy-induced neutropenia, a separate indication built on the PROTECTIVE-2 trial, so the compound has prior FDA engagement, though that program and DUBLIN-4 are distinct.
The practical question now is whether the Phase 2 durability data survives randomization against docetaxel alone in a post-ICI population at scale. The interim analysis, whenever it arrives, will be the first controlled test of that hypothesis, and the outcome determines whether a program built on a 47-patient signal can hold up at 442.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
